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Abstract: Left ventricular assist devices (LVAD) are currently used to either “bridge” patients with terminal congestive 
heart failure (CHF) until cardiac transplantation is possible or optionally for patients with contraindications for transplan-
tation (“destination therapy”). Mechanical support is associated with a marked decrease of cardiac dilation and hypertro-
phy as well as numerous cellular and molecular changes (“reverse cardiac remodeling”), which can be accompanied by 
improved cardiac function (“bridge to recovery”) in a relatively small subset of patients with heart transplantation no 
longer necessary even after removal of the device (“weaning”). In the recent past, novel pharmacological strategies have 
been developed and are combined with mechanical support, which has increased the percentage of patients with improved 
clinical status and cardiac performance. Gene expression profiles have demonstrated that individuals who recover after 
LVAD show different gene expression compared to individuals who do not respond to unloading. This methodology holds 
promise for the future to develop read out frames to identify individuals who can recover after support. Aside from de-
scribing the morphological changes associated with “reverse cardiac remodeling”, this review will focus on signal trans-
duction, transcriptional regulation, apoptosis, cell stress proteins, matrix remodeling, inflammatory mediators and aspects 
of neurohormonal activation in the failing human heart before and after ventricular unloading. 
Key Words: Congestive heart failure (CHF), ventricular unloading, left ventricular assist device (LVAD), reverse cardiac re-
modeling, morphology, weaning. 
1. INTRODUCTION 
  Chronic heart failure (CHF) is a major cause of morbidity 
and mortality in both western industrialized and developing 
nations and causes considerable economic burden to the 
medical systems [1-3]. Despite medical treatment is continu-
ously being improved, cardiac transplantation is the only 
curative approach to CHF of various aetiologies. However, 
the number of donor hearts is limited and has been declining 
since the last decade of the 20
th century [2]. The need for 
intervention in acute heart failure and the long waiting peri-
ods for donor organs consequently led to the development of 
left ventricular assist devices (LVAD). LVAD are electri-
cally powered either pulsatile or non-pulsatile pumps or tur-
bines, which can be installed extracorporally or intrathoraci-
cally parallel to the circulation, i.e. they transport blood from 
the left ventricle to the ascending aorta and thereby provide 
profound volume and pressure reduction and restore sys-
temic blood pressure and flow to near normal levels. This 
leads to a normalization of the neurohormonal and local cy-
tokine milieu contributing to myocardial recovery [4,5]. 
LVAD are used either as a “bridge to transplantation” or to 
re-establish basic cardiac function without transplantation 
(“bridge to recovery”). Optionally, it can be used in patients 
with contraindications for transplantation (“destination ther-
apy”). Improved survival rates of patients treated with 
LVAD until cardiac transplantation compared to medical 
treatments could be demonstrated [4,6]. The structural and 
molecular changes occurring in the myocardium during CHF 
(“cardiac remodeling”) have been intensively studied in the  
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past [7,8]. There is now compelling evidence that prolonged 
near-total unloading of the left ventricle in CHF is associated 
with numerous morphological and molecular changes in the 
myocardium (“reverse remodeling”) [9,10], which can be 
accompanied by functional improvement and decreased car-
diac dilation [11]. Despite encouraging data on morphologi-
cal and molecular changes of the affected heart, clinical car-
diac recovery sufficient to allow device removal (“weaning”) 
is reported to occur only in a small subset of individuals [12-
16]. In general, it is agreed on that cellular and molecular 
improvement is greater than clinical cardiac recovery [17]. 
However, Birks and co-workers were able to show myocar-
dial recovery in a percentage as high as 75% of their studied 
patients after combined use of ventricular unloading and an 
aggressive pharmacological regimen consisting of lisinopril 
(angiotensin converting enzyme inhibitor), carvedilol (-
receptor antagonist), spironolactone (aldosterone antagonist) 
and lorsatan (angiotensin II antagonist), which are known to 
reduce ventricular remodeling. This approach is followed by 
administration of clenbuterol, a selective 2-agonist, helping 
to prevent cardiomyocyte atrophy in response to long-term 
unloading [18]. Although LVAD no longer increase the risk 
of transplantation itself [2], there is considerable periopera-
tive morbidity and mortality with patient survival between 
60 and 75%. The major limitations to survival are advanced 
age, sepsis and hepatic/renal dysfunction as well as device-
related problems including HLA antibodies, infection and 
device failure [19]. Our group reported on a case of hyper-
sensitivity myocarditis, which resolved after ventricular un-
loading [20]. Mechanical ventricular support does not influ-
ence the survival rate after transplantation or the incidence 
and severity of rejection episodes [21]. In addition, patients 
supported by LVAD have an increased quality of life (QOL) 
and functional status compared individuals with medical 
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jor morphological and molecular changes that occur in the 
heart during “reverse cardiac remodeling” by ventricular 
unloading, including some of the latest results from our 
group. 
2. CHRONIC HEART FAILURE: CARDIAC “RE-
MODELING” VERSUS “REVERSE REMODELING” 
AFTER VENTRICULAR UNLOADING BY LVAD 
  CHF is a complex disease process with a step-wise pro-
gression, eventually leading to terminal pump failure, inter-
stitialfibrosis,cardiacdilation,arrhythmias and cardiac death. 
Various stimuli can initiate this process, which is combined 
with compensatory attempts of the body to counteract by 
several pathobiological mechanisms. After unloading, the 
deteriorated cardiac function can partially recover, which is 
accompanied by numerous changes on different cellular and 
molecular levels and systems including changes in gene ex-
pression profiles (“reverse remodeling”) (for review see 
[10]). 
2.1. Morphological Changes of the Myocardium During 
CHF (“Cardiac Remodeling”) 
  Myocardial remodelling denotes acquired pathological 
states of the heart resulting in rearrangement of normally 
existing structures and generally concerns the two compo-
nents of the cardiovascular system, i.e. the myocardium and 
the vessels, the structure of both can be altered by unfavour-
able conditions caused by several noxious stimuli that im-
pose increased biomechanical stress to the cardiomyocytes 
[22]. In response to an increased workload, individual car-
diomyocytes react by adaptive hypertrophic growth, i.e. they 
increase in cell size, volume and mass, or undergo apoptosis, 
respectively [23,24]. As a result, there is organ enlargement, 
cardiac dilation and increased sphericity [22]. Although salu-
tary at the beginning by reducing wall tension, hypertrophy 
eventuallybecomesa maladaptive process, leading to chronic 
heart failure (CHF) and cardiac mortality [23,24]. Dilation is 
followed by increased ventricular wall stress resulting in 
decreased coronary blood flow, impaired pump function and 
diminished cardiac output [25]. Moreover, interstitial fibrosis 
is observed, further hindering systolic and diastolic cardiac 
function [26].  
2.2. Morphological Changes of the Myocardium During 
CHF After Ventricular Unloading (“Reverse Cardiac 
Remodeling”) 
  After unloading, an overall reduction of organ size can be 
observed radiologically. Echocardiography reveals decreased 
left ventricular diameter and an increased ejection fraction 
[27-29]. Among others, we have shown a significant reduc-
tion of cardiomyocyte diameters after LVAD). Decreased 
length and volume were repeatedly described as the morpho-
logical correlate of decreased organ size [9,30,31]. Whether 
unloading is associated with decreased interstitial fibrosis or 
not is still unresolved. Some authors indicate, that a striking 
reduction of interstitial connective tissue can be observed 
after LVAD [32]. Bruckner and co-workers confirmed this 
finding and further report on a reduction of the total collagen 
content in 9 out of 18 patients with concomitant improve-
ment of the ejection fraction. The authors suggest that the 
amount of fibrosis and cardiomyocyte hypertrophy before 
LVAD support is predictive in terms of improvement of the 
ejection fraction [33]. In contrast, Taketani and co-workers 
found increased interstitial fibrosis after LVAD support, and 
another group observed a slight increase of cardiomyocyte 
diameters together with increased fibrosis after unloading 
[34,35]. Our group was unable to show any changes of inter-
stitial fibrosis between before and after unloading [36]. 
These conflicting results indicate the difficulties in proper 
assessment of changes of interstitial fibrosis rather than dif-
ferences between the studied cohorts. As indicated previ-
ously we think [10], that the striking differences obtained 
concerning this parameter by various groups is due to meth-
odological problems. Computerized semiquantitative analy-
sis of Sirius Red stained myocardial specimens yield density 
data such as sectional profile areas per unit area or three-
dimensional quantities per unit volume. Interpretation of 
such data is difficult, because changes of the structures of 
interest can not be detected when both the latter and the ref-
erence structure show equivalent changes, i.e. when changes 
of both structures are correlated: this is the so-called refer-
ence trap in stereology, meaning that false data are obtained 
when both the structure measured (amount of fibrosis) and 
the reference structure (the heart) simultaneously show 
changes in their volumes. This is important to bear in mind 
when investigating ratios before and after LVAD, because 
the reference volume (i.e. the heart) decreases in size due to 
hypertrophy regression. Thus, one approach to circumvent 
the reference trap problem in the measurement of interstitial 
fibrosis in future studies would be to assess the heart volume 
based on MRI studies and extrapolate the volume fraction of 
interstitial connective tissue measured on histological sec-
tions to the absolute volume of fibrosis [10,37-40]. 
2.3. Molecular Mechanisms Involved in Cardiac “Re-
modeling” and “Reverse Remodeling” 
  Numerous molecular systems become progressively al-
tered and/or disturbed during CHF, partly causal to CHF and 
partly as an after effect of proceeding CHF. Some, but not all 
of them are regarded as initially compensatory mechanisms 
that become deleterious as the disease progresses. Almost all 
molecular systems investigated show changes associated 
with ventricular unloading and simultaneous drug therapy. 
Klotz and co-workers showed that angiotensin converting 
enzyme inhibition during unloading resulted in decreased 
interstitial collagen content and myocardial stiffness com-
pared to controls, who were only mechanically supported 
[41]. “Reverse cardiac remodelling” can be viewed as a re-
sult of both drug-mediated and mechanical LVAD-mediated 
effects. 
2.3.1. Extracellular Matrix 
  The extracellular matrix is necessary for the proper 
alignment and the coordinated process of transduction of the 
contractile force generated by the cardiomyocytes. During 
CHF, severe changes in the extracellular matrix turnover are 
observed, mediated by members of the matrixmetalloprote-
inase family (MMP)[42-44]. In summary, MMP are upregu-
lated during CHF, whereas their inhibitors, the TIMPS (tis-
sue inhibitors of matrix metalloproteinases) are downregu-
lated. In particular, MMP3 and MMP9 were found to be in-
creased during CHF, while MMP2 was unaltered. MMP 3 is Morphological and Molecular Changes  Current Cardiology Reviews, 2008, Vol. 4, No. 3    159
important because of its ability to degrade a wide range of 
extracellular matrix (ECM) components including collagen 
and to activate latent MMP. This altered expression of MMP 
and TIMPS favours degradation and destabilization of the 
mechanical scaffold of the heart resulting in ventricular dila-
tion [44]. In contrast, decreased expression of MMP 1 and 9 
and upregulation of TIMP 1 and 3 were observed after ven-
tricular unloading followed by a decreased extracellular ma-
trix turnover resulting in less pronounced ventricular remod-
eling and decreased dilation. Recently it was reported that 
“reverse remodeling” follows a biphasic pattern. Initially, an 
increase in Type I and Type III collagen turnover occurs, 
which is paralleled by a volume increase of the ECM. Sub-
sequently, this turnover decreases as ECM volume decreases, 
which results in a restoration of the collagen network [45]. 
The biological mechanism underlying these changes might 
be that MMP are induced by mechanical stretch of cardio-
myocytes. In summary, ventricular unloading reduces wall 
tension by volume- and pressure reduction and favours the 
physiological homeostatic balance between MMP and TIMP, 
thereby facilitating partial geometrical reshaping of the heart 
[43] (Fig. 1). 
Fig. (1). Simplified schematic diagram of the role of matrix metal-
loproteinases (MMP) and their inhibitors (TIMPS) during chronic 
heart failure (CHF) and reverse cardiac remodelling: increased ex-
pression of MMP and decreased expression of TIMPS during CHF 
increase turnover of extracellular matrix constituents and favour 
cardiac dilation, these mechanisms are reversed after ventricular 
unloading and therefore induce geometrical reshaping of the heart.
2.3.2. Cardiomyocyte Biology 
2.3.2.1. -Adrenergic Signal Transduction
  Inotropy, chronotropy, dromotropy and lusitropy are all 
regulated by -adrenergic receptors and the subsequent acti-
vation of the G protein-adenylylcyclase signal transduction 
cascade. -adrenergic receptors are functionally coupled to G 
proteins and serve as targets of protein kinase A and C as 
well as -adrenergic receptor kinases (-ARK). -adrenergic 
receptor signalling can be altered by (1) receptor downregu-
lation due to decreased synthesis or to increased sequestra-
tion (long-term regulation requiring hours) and (2) receptor 
dysfunction as a result of uncoupling from the signal trans- 
ducing G proteins (GS) (short term regulation requiring sec-
onds) and induced by receptor  phosphorylation by protein 
kinases A and C and -ARK [46]. Isolated cardiomyocytes 
from failing human hearts show a decreased response to -
adrenergic agonists. The density of -adrenergic receptors in 
the myocardium of patients with either dilated cardiomyopa-
thy (DCM) or ischemic cardiomyopathy (ICM) is markedly 
decreased [47]. After unloading, restoration of -adrenergic 
receptor density to near-normal levels is observed. Moreo-
ver, response to -adrenergic stimulation by muscles from 
unloaded hearts is similar to non-failing hearts. Of note, 
these changes were not dependent on the duration of ven-
tricular support and receptor density alone did not predict the 
magnitude of the inotropic response. The mechanism under-
lying this functional cardiomyocyte improvement may in-
clude normalization of the plasma neurohormones and the 
decrease in both plasma and cardiac cytokine levels after 
LVAD support [48] (Fig. 2). 
Fig. (2). During CHF, besides receptor uncoupling, the density of 
-adrenoreceptors and their responsiveness are decreased leading to 
decreased cardiac function and contractility. Some of these molecu-
lar changes are reversed by mechanical ventricular support.
2.3.2.2. Ca
2+ Homeostasis
  Contractile dysfunction during CHF of either aetiology is 
associated with alterations of Ca
2+ cycling [49]. Downregu-
lated gene expression of sarcoplasmic endoreticular Ca
2+
ATPase subtype 2a (SERCA2a), of the sarcoplasmic reticu-
lar (SR) ryanodine-sensitive Ca
2+ release channel (ryanodine 
receptor [RyR]), and altered regulation of the sarcolemmal 
Na
+/ Ca
2+ exchanger have been reported and appear to corre-
late with contractile dysfunction [50]. After LVAD support, 
several authors indicate a recovery of cardiomyocyte con-
tractile strength, coinciding with normalization of magnitude 
and time course of the Ca
2+ transient as well as an increased 
gene expression and protein level of SERCA2a [51,52]. Ter-
racciano and co-workers have demonstrated that clinical 
recovery from terminal CHF after pharmacological and me-
chanical support is associated with modifications in excita-
tion-contraction coupling, and sarcoplasmatic Ca
2+ homeo-
stasis in particular, and not with a reduction of cardiomyo-
cyte cell size. These findings underscore the importance of 
Ca
2+ cycling in CHF and its treatment [53]. 160 Current Cardiology Reviews, 2008, Vol. 4, No. 3 Baba and Wohlschlaeger 
2.3.2.3. Natriuretic Peptides and Chromogranin A
  CHF due to divergent aetiologies is, among other mo-
lecularchanges,characterizedbyactivation of neurohormonal 
systems: catecholamines, natriuretic peptides (NP) and com-
ponents of the renin-angiotensin axis are increased in CHF 
and were found to have pathophysiological and prognostic 
implications. Some of these molecules exert local paracrine 
activation, but their plasma levels were demonstrated to be 
markers of clinical outcome. Cardiac atrial (ANP) and B-
type natriuretic peptides (BNP) are crucial for the mainte-
nance of arterial pressure and volume homeostasis [54-56]. 
Moreover, they act in an antihypertrophic (ANP) and antifi-
brotic (BNP) manner via guanylyl cyclase A (GC-A) [57]. 
Both ANP and BNP are elevated in the plasma of CHF pa-
tients and these peptide levels are significantly correlated 
with disease severity. Interestingly, there is a markedly de-
creased diuresis/natriuresis, vasodilation and vascular syn-
thesis of cGMP in response to exogenous ANP and BNP, 
indicating a downregulation or impaired receptor or postre-
ceptor responsiveness of GC-A in peripheral tissues from 
CHF patients. Involvement of enhanced clearance of natri-
uretic peptides was also suggested [58]. We investigated 
changes in ANP, BNP and the natriuretic peptide receptor 
(NPR-C) by quantitative reverse transcriptase polymerase 
chain reaction (RT-PCR) and determined the activity of the 
ANP/GC-A system. Increased cardiac ANP and BNP ex-
pression in CHF patients is associated with increased expres-
sion of the NP metabolizing NPR-C receptors and blunted 
responsiveness of GC-A to ANP by reduced cGMP synthe-
sis. “Reverse remodeling” after unloading reverses these 
changes and re-establishes the local responsiveness of GC-A 
to ANP. Cardiac expression of ANP, BNP and NPR-C 
mRNA correlated significantly with cardiomyocyte diame-
ters. In contrast to the latter, the levels of the natriuretic pep-
tides are fully reversed to the level of the controls, indicating 
that their expression is partly independent of cardiac hyper- 
trophy and regulated by CHF associated factors such as car-
diomyocyte stretch [59] (Fig. 3). 
  Chromogranin A (CGA) is an acidic calcium-binding 
protein (49 kDa) and is the major soluble constituent in se-
cretory vesicles throughout the neuroendocrine system [60]. 
CGA was found to be significantly upregulated during CHF 
and is co-stored with catecholamines and NP. CGA is se-
creted into the circulation with a long-term plasma half-life 
of approximately 18 minutes. Thus, CGA constitutes an in-
dex of a steady activation of the neuroendocrine system 
rather than a transient response to stress [61,62], and serves 
as an independent prognostic marker of CHF severity and 
mortality in line with ANP and BNP [63]. CGA is a pro-
hormone precursor and is proteolysed by proteases via nu-
merous cleavage sites [64] in a tissue-specific manner [65], 
resulting in the formation of catestatin and vasostatins, which 
exert a autocrine/paracrine negative feedback control on lo-
cal catecholamine release [66] and vascular dilation [67]. 
Vasostatins exert a negative inotropic effect on isolated frog 
and eel hearts and counteract the actions of -adrenergic 
drugs [68,69]. BNP and CGA are co-stored in the myocar-
dium of patients with dilated cardiomyopathy, whereas this 
co-localisation was not found in healthy controls [70]. We 
investigated the expression of natriuretic peptides (NP) and 
CGA by immunohistochemistry and morphometric quantifi-
cation before and after LVAD. In a different set of patients, 
CGA was evaluated in the plasma. We demonstrated that in 
line with ANP and BNP, CGA is significantly increased in 
CHF compared to healthy controls and decreased by ven-
tricular support. Moreover, sarcoplasmic colocalization of 
BNP and CGA is diminished after unloading. However, due 
to its low expression the negative regulation of CGA is not 
reflected by plasma levels, thus CGA does not appear to be 
an appropriate biomarker for the monitoring of “reverse car-
diac remodeling” after unloading (accepted manuscript) (Fig. 
4A-F). 
Fig. (3). CHF and cardiac hypertrophy are associated with increased expression of ANP and BNP (natriuretic peptides, NP), which are con-
sidered to be induced by tensile stretch during cardiac dilation. The NP receptor responsiveness is blunted. Chromogranin A, another neu-
roendocrine protein is increased during CHF and has been shown to exert cardiodepressive effects in animal studies. LVAD is associated 
with decreased expression of NP and Chromogranin A. Morphological and Molecular Changes  Current Cardiology Reviews, 2008, Vol. 4, No. 3    161
2.3.2.4. Inflammatory Factors: Cyclooxygenase-2 and 
Phosphorylated Akt
 (Thr308)
  Patients with CHF are characterized by systemic inflam-
mation, as evident by raised circulating levels of several in-
flammatory cytokines with increasing levels as the disease 
progresses. Apart from the myocardium, several other cell 
and tissue types can contribute to the inflammatory response 
including leucocytes, platelets, tissue macrophages and en-
dothelial cells. These cells synthesize and secrete inflamma-
tory cytokines such as tumor necrosis factor (TNF) , inter-
leukin (IL)-1 and IL-6, as well as chemokines [71-75]. Of 
note, in CHF increased levels of inflammatory mediators do 
not seem to be accompanied by a corresponding increase in 
anti-inflammatory cytokines such as IL-10 [72]. Moreover, 
increased plasma/serum levels of inflammatory mediators 
are tightly associated with deterioration of functional cardiac 
performance reflected by diminished left ventricular ejection 
fraction (LVEF) [72-74]. Importantly, the release of inflam-
matory mediators from the failing myocardium is not neces-
sarily related to necrotic and/or apoptotic cell death of car-
diomyocytes. On the contrary, activation of NF-B, a major 
inflammatory mediator in the failing myocardium, has anti-
apoptotic effects [76]. Mechanical ventricular overload and 
shear stress, hypoxia, ischemia and oxidized low density 
lipoprotein cholesterol have been shown to be potent induc-
ers of inflammatory factors from different cell types includ-
ing cardiomyocytes [77-81]. An interaction between inflam-
matory response and activation of neurohormonal systems 
was suggested [82,83]: animal studies and in vitro experi-
ments have shown that angiotensin II (ATII) activates circu-
lating leucocytes and promotes adhesion to the endothelium, 
which in response activates adhesion molecules, chemokines 
and inflammatory cytokines resulting in the production of 
reactive oxygen species (ROS) and induction of the tran-
scription factor NF-B [84]. Similar observations have been 
made for aldosterone [85,86]. A series of experimental stud-
ies have demonstrated that inflammatory cytokines such as 
TNF, IL-1 and MCP-1 may directly contribute to the 
pathogenesis of CHF by inducing contractile dysfunction, 
ventricular dilation, cardiomyocyte hypertrophy, apoptosis 
and fibrosis [87-89]. 
  Cyclooxygenase-2 (COX-2) is rapidly induced by vari-
ous cytokines [90] and hypoxia [91], both considered hall-
marks of CHF [92]. Consequentially, increased expression of 
COX-2 has been demonstrated in the failing myocardium 
[93]. COX-2 expression is regulated, among others [94], 
through the PI3/Akt pathway, a major player in cell growth 
Fig. (4). Colocalisation of BNP and Chromogranin A during CHF (A), which is considerably decreased by unloading (B). Normal control 
hearts are devoid of this colocalisation (C). Red arrow indicates Chromogranin A, green arrow indicates BNP and yellow arrows indicate 
colocalisation of Chromogranin A with BNP. 
Despite being significantly decreased in the myocardium after unloading, owing to its low expression in the myocardium, Chromogranin A 
plasma levels do not reflect hypertrophy regression after LVAD (D). ANP and BNP are significantly decreased in the plasma after unloading 
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and apoptosis [95]. Overexpression of COX-2 was shown to 
induce Akt phosphorylation at the threonine residue 308 
(Thr308), but not at the serine residue 473 (Ser473) in vitro,
indicating that the COX-2 induced growth stimulus is medi-
ated mainly by phosphoinositide-dependent protein kinase-1 
controlled Akt phosphorylation [96]. Moreover, Akt itself 
was suggested as a promoter of cardiac hypertrophy [97]. 
We investigated COX-2 and phosphorylated Akt both at 
(Thr308) and (Ser473) and phosphorylated Erk by immuno-
histochemistry and quantitative morphometry. COX-2, pAkt 
(Thr308), pAkt 
(Ser473) and pErk positive cardiomyocytes were 
significantly increased in CHF compared to normal controls 
and were significantly decreased by unloading. Moreover, a 
significant positive correlation between COX-2 and cardio-
myocyte diameters as well as pAkt 
(Thr308) was noted. In par-
ticular, COX-2 positive cardiomyocytes showed significantly 
larger diameters than COX-2 negative cardiomyocytes, sug-
gesting that COX-2 plays a crucial role in hypertrophic 
growth during CHF (Fig 5). Moreover, there was abundant 
colocalization of COX-2 and pAkt 
(Thr308) seen in im-
munofluorescence doublestaining, suggesting a direct mo-
lecular cross-talk between the two proteins, as was suggested  
Fig. (5). Cardiomyocytes with expression of Cyclooxygenase-2 
have significantly larger diameters than COX-2 negative cardio-
myocytes.
by in vitro studies (Fig. 6A-C)[96]. Furthermore, numerous 
animal studies have shown that hypertrophy and functional 
deterioration occur upon COX-2 overexpression, and are 
ameliorated by administration of COX-2 inhibitors, suggest-
ing that COX-2 exerts cardiodepressive effects [98-100]. In 
summary, we demonstrated a negative regulation of COX-2 
after ventricular unloading and suggest a central role for 
COX-2 in cardiomyocyte hypertrophy, since only COX-2 
positive cardiomyocytes showed significant hypertrophy 
regression after LVAD (Fig. 7). Moreover, this might be one 
of the interfaces between neurohormonal activation, systemic 
inflammation and maladaptive cardiac hypertrophy [101]. 
2.3.2.5. Signal Transduction and NF-B
2.3.2.5.1. Transduction Pathways
  Among others, three major signal transduction pathways 
have been shown to be involved in the pathogenesis of car-
diachypertrophyand“remodeling”: (1) the mitogen-activated 
protein kinases (MAPK) with the extracellular signal-related 
kinases (Erks), c-jun N-terminal protein kinases (JNKs) and 
p38 MAPK subfamilies [102]; (2) the Ca
2+/Calmodulin acti-
vated protein kinase (CaM kinase) and phosphatase (cal-
cineurin) [103], and (3) the protein kinase B/Akt and its 
downstream target glycogen synthase kinase 3 (GSK3)
[104]. All three pathways become activated during CHF in 
humans. Whereas the Erks are activated by hypertrophic 
stimuli such as phenylephrine, angiotensin II (ATII) and 
endothelin-1 [102], the JNK and p38 MAPK are activated by 
cellular stress and seem to be involved in apoptotic cell death 
[105]. Apart from acting as an anti-apoptotic factor, Akt is a 
major repressor of cardiac hypertrophy by inhibitory phos-
phorylation of GSK3 [106]. The phosphatidylinositol-3-OH 
kinase (PI3K) is a signalling system that acts through Akt 
and p70S6 kinase, which is a key factor in angiotensin II 
(ATII) receptor type 2 mediated cardiac hypertrophy [107]. 
We investigated the activity of the mitogen-activated protein 
kinases (MEKs), Erks, Akt, GSK3, p70S6 kinase, JNKs 
and p38 in terminal CHF before and after unloading. West-
ern blot analysis revealed a dramatic decrease in dually 
phosphorylated active forms of Erk-1 and Erk-2 after me-
chanical support. Also the erk-activating kinases (MEK-1/2) 
were shown to be significantly less phosphorylated after 
LVAD. After unloading, Akt is inactivated, whereas GSK3
becomes activated. Besides Akt, another kinase involved in 
the PI3K/Akt pathway, p70S6 kinase showed a dramatic 
decrease in its phosphorylation in a subset of patients. De-
Fig. (6). Significant Colocalisation of COX-2 (red signals) and p-Akt 
(Thr308) (green signals) resulting in yellow overlay signals (see arrows) 
during CHF (A). This is reversed by LVAD support (B). Controls do not show signals for COX-2 but only few for p-Akt 
(Thr308) (C). Morphological and Molecular Changes  Current Cardiology Reviews, 2008, Vol. 4, No. 3    163
spite p70S6 kinase and its isoform p85S6 are associated with 
cardiomyocyte hypertrophy mediated by angiotensin II 
(ATII) receptor type 2, there was no correlation between 
cardiomyocyte diameter reduction and phosphorylation of 
p70S6 kinase. In contrast, neither the JNK nor the the p38-
mediated signalling cascades were altered under LVAD sup-
port in this study, suggesting specific regulation of kinase 
signalling after mechanical support in humans in vivo. In 
summary, our findings underscore the emerging evidence of 
MEK/Erks and Akt/GSK3 in the pathogenesis and regula-
tion of cardiac hypertrophy. The inactivation of MEK/Erks 
and the activation of GSK3 after LVAD are in line with the 
opposing effects of these two signalling cascades with regard 
to cardiac “reverse remodeling” [108]. 
2.3.2.5.2. Transcription Factor NF-B
 NF-B is a crucial regulator of genes involved in anti-
apoptosis and cellular responses to stressful factors [109]. 
Consequently, upregulation of NF-B was demonstrated in 
the failing myocardium [93]. We investigated the immuno-
histochemical expression of the active p65 subunit of NF-B
before and after unloading and found a significant about two-
fold decrease upon unloading. Moreover, gel-shift assays 
were performed to test whether the immunoreactivity for 
active NF-B correlates with DNA binding activity, which 
was significantly decreased after unloading. In summary, we 
identified abundant NF-B activity in cardiomyocytes during 
CHF, which is drastically reduced by mechanical support. 
Therefore, NF-B appears to be to be a specific and reverse 
functional response to molecular signals induced by pres-
sure- and volume overload. Since NF-B regulates the ex-
pression of genes encoding for TNF, IL-6 and heme-
oxygenase, which are increased in CHF and decreased after 
LVAD, NF-B may regulate a subset of genes crucially in-
volved in “reverse remodeling” [110]. 
2.3.3. Apoptosis 
  Apoptosis is believed to contribute to cardiomyocyte 
dropout and progressive decline in left ventricular function 
during CHF [111]. Several different apoptotic mechanisms 
are at work in CHF and are shortly reviewed in the following 
paragraph. 
2.3.3.1. (Extrinsic) Death Receptor Pathway 
 Fas/Fas-ligand  pathway.  There is evidence that the 
Fas/FasL system participates in various types of stress-
induced apoptosis in the heart, where cellular stressful stim-
uli sensitize cardiomyocytes to Fas in vitro [112]. Elevated 
levels of soluble Fas ligand and Fas mRNA has been demon-
strated in the failing myocardium [113]. The myocardial Fas 
system (APO-1/CD95) was shown to respond very sensitive 
and promptly to ventricular pressure- and volume changes 
[114]. After unloading, the expression of the anti-apoptotic 
protein FasExo6Del is decreased, hence decreased cardio-
myocyte susceptibility to apoptosis can be assumed [115]. 
2.3.3.1.1. TNF-Receptor Pathway
  Cardiomyocytes can undergo apoptosis after stimulation 
by TNF, which is increased in the myocardium during CHF 
[116]. However, a significant decrease of TNF in the myo-
cardium of LVAD supported patients was demonstrated 
[117]. In this respect it must be mentioned, that the role of 
TNF in the heart is not entirely clear. It has been shown to 
be beneficial in an animal model when administered as a pre-
treatment of ischemia/reperfusion [118]. Further studies are 
needed to definitively clear the role of TNF in CHF. 
2.3.3.1.2. (Intrinsic) Mitochondrial Pathway
  This apoptotic pathway plays a crucial role in CHF. It 
was shown that release of cytochrome c from the mitochon-
Fig. (7). Stressful stimuli lead to COX-2 expression in some, but not all cardiomyocytes, which become hypertrophic leading to organ en-
largement. Ventricular unloading significantly decreases COX-2 expression, which is significantly correlated with hypertrophy regression, 
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dria and activation of caspase 3 occurs in CHF patients 
[111]. 
2.3.3.1.3. Bcl-2 Family
  These proteins show either pro-apoptotic (Bcl-2 and Bcl-
xL) or anti-apoptotic properties (Bax, Bad, Bid, Bnip3), pri-
marily acting via the mitochondrial pathway. Upon hypoxia 
or mechanical stretch, both kinds of Bcl-2 family proteins 
were found to be induced during terminal CHF [119,120]. 
2.3.3.1.4. Apoptosis and Ventricular Unloading
  Long-term unloading is associated with changes of gene 
expression involved in the regulation of apoptosis. Upregula-
tion of Bcl-xL was demonstrated after LVAD, suggesting 
that susceptibility to apoptosis is decreased upon unloading 
[115]. Also data from our group support the notion of re-
duced apoptotic index after mechanical support [108]. 
2.3.4. Cell Stress Associated Factors: Heme Oxygenase-1 
and Metallothionein 
2.3.4.1. Heme Oxygenase-1
  Heme oxygenase-1 (HO-1, HSP 32) is a member of fam-
ily of heat shock (cell stress) proteins induced by noxious 
stimuli. HO-1 was demonstrated to act cell-protective and 
anti-apoptotically. Hence, increased expression of HO-1 in-
dicates profound cellular stress [121]. In CHF, HO-1 is sig-
nificantly increased in cardiomyocytes and to a lesser extent 
in arterial smooth muscle cells, endothelial cells and inflam-
matory cells. After unloading, the HO-1 expression recedes 
to the level of control hearts. Moreover, in the same study 
increased HO-1 expression in cultured rat cardiomyocytes 
exposed to hypoxia and declined to normal levels during 
normoxic conditions [122]. 
2.3.4.2. Metallothionein
  Metallothionein (MT) is a cell stress protein involved in 
the inactivation of free reactive oxygen species (ROS) [123]. 
MT expression was in line with HO-1 found to be increased 
in CHF compared to controls and significantly decreased 
after unloading. Decreased numbers of MT-1 positive car-
diomyocytes were mainly found in subendocardial areas 
indicating (reversible) hypoxic damage, further underscoring 
the notion that unloading improves the myocardial oxygen 
supply [31].  
2.3.5. Gene Profiling Changes after Ventricular Unloading 
  Some studies investigated differences of gene expression 
profile in both CHF and after unloading. With regard to the 
fact, that morphological and molecular changes are clearly 
more evident than clinical recovery, read-out frames for pa-
tients who can be expected to recover sufficiently for device 
removal versus patients who have fewer changes to be 
weaned from the device are needed. Furthermore, these in-
vestigations might be the basis for future therapeutic strate-
gies and concepts. One study investigated the effect of un-
loading on myocardial gene expression. Profiling gene ex-
pression was compared before and after LVAD support in 
seven patients with idiopathic dilated cardiomyopathy and 
end-stage heart failure. A total of 130 gene transcripts 
achieved the strict criteria for upregulation and 49 gene tran-
scripts for downregulation after LVAD support. In line with 
the proteomic findings, upregulated genes included a large 
proportion of transcription factors, genes related to cell 
growth/apoptosis/DNA repair, cell structure proteins, me-
tabolism, and cell signaling/communication. Hall and co-
workers performed statistical analysis of a gene expression 
library of 19 paired human myocardial samples and found a 
set of 22 genes that were downregulated and 85 genes that 
were upregulated in response to mechanical unloading. The 
analysis revealed a high percentage of genes involved in the 
regulation of vascular networks including neuropilin-1 (a 
VEGF receptor), FGF9, Sprouty1, stromal-derived factor 1, 
and endomucin. Taken together these findings suggest that 
mechanical unloading alters the regulation of vascular orga-
nization and migration in the heart. Moreover, GATA-4 
binding protein, a critical mediator of myocyte hypertrophy, 
was significantly downregulated following mechanical un-
loading. In summary, these findings may have important 
implications for defining the role of mechanical stretch and 
load on autocrine/paracrine signals directing vascular orga-
nization in the failing human heart and the role of GATA-4 
in orchestrating reverse myocardial remodeling [124]. An-
other important finding concerning gene profiling changes 
encoding for cytoskeletal proteins selectively for recovery 
versus non-recovery was reported by Birks and co-workers: 
they investigated the gene expression encoding for sar-
comeric and non-sarcomeric proteins before and after LVAD 
and found that recovery is associated with specific changes 
in gene expression. In particular, an increased gene expres-
sion of the nuclear protein Lamin A/C was found in recov-
ery, but not in non-recovery. Interestingly, Lamin A/C gene 
mutations have been found in families with dilated cardio-
myopathy. Despite providing structural integrity of the nu-
clear membrane, Lamin A/C interacts with intermediate 
filaments of the sarcomere, the actin-based cytoskeleton and 
the sarcolemma [37], suggesting recovery of that system 
after unloading. Moreover, changes in six genes for dystro-
phin-like proteins occurred. Dystrophin is thought to provide 
structural support for the cardiomyocytes and mutations can 
result in cardiomyopathy. Disruption of Dystrophin was 
demonstrated in CHF, which reversed upon unloading 
[38,39]. The most striking finding of this study, however, 
were changes in -integrin signalling. Integrins are trans-
membrane receptors linking the extracellular matrix to the 
cytoskeleton. They are expressed on numerous cell types in 
the cardiovascular system and are involved in gene expres-
sion, cell migration, cell proliferation, differentiation and cell 
death. Moreover, they have been shown to have function in 
mechanotransduction (cellular mechanism by which a me-
chanical stimulus is converted in a chemical signal) in re-
sponse to physiological and pathophysiological signals [125-
127]. Integrins bind directly to components of the cytoskele-
ton through their cytoplasmic tails and can orchestrate 
changes in cellular architecture. However, an important limi-
tation of this study is, that the recovered group of patients 
were treated with clenbuterol, whereas the non-recovered 
group was not and the effect of the drug on the cytoskleleton 
remains unclear; however, a small number of clenbuterol-
treated non-recovered patients showed changes similar to 
other untreated patients. In conclusion, this study docu-
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coding for both sarcomeric and non-sarcomeric proteins in 
patients who recovered and who did not, suggesting that the 
cytoskeleton plays an important role in both “reverse remod-
eling” and clinical myocardial recovery [40]. The results 
yielded by this kind of methodology might serve as one pos-
sible read-out frame for patients who can be weaned from 
the device without subsequent transplantation. Moreover, 
specific gene expression profiles allow for the differentiation 
of ischemic versus non-ischemic cardiomyopathy [128].  
3. CONCLUSIONS AND FUTURE PERSPECTIVES 
  Numerous noxious stimuli such as chronic ischemia, in-
flammation or genetic alterations can affect the myocardium 
and induce rather unspecific compensatory and adaptive 
changes including cardiomyocyte hypertrophy. Albeit salu-
tary at the beginning these adaptive mechanisms may be-
come maladaptive and deleterious over time and eventually 
lead to impaired cardiac function. The increased cardiac wall 
stress and local ischemia may be mechanisms that activate 
numerous molecular and cellular responses. Protective 
mechanisms are overrun and the myocardium cannot further 
adaptto increased biomechanical stress. Neurohormonal acti-
vation, inflammatory mediators, alterations in -adrenergic 
signal transduction and Ca
2+ metabolism and interstitial fi-
brosis further impair cardiac function (Fig. 8A). Despite ever 
improving medical strategies, cardiac transplantation re-
mains the only curative therapeutic approach until now. Due 
to the shortage of suitable donor organs, LVAD are currently 
used to maintain cardiac in patients with terminal CHF until 
a donor organ is available or optionally for patients with con-
traindications for transplantation as a permanent therapy. As 
outlined above, the use of unloading by LVAD is associated 
with changes on the gross anatomical, histological, cellular, 
molecular and genetic level (Fig 8B). Although these results 
A
B
Fig. (8). Schematic overview of molecular and morphological changes during CHF (A) and after LVAD support (B). 166 Current Cardiology Reviews, 2008, Vol. 4, No. 3 Baba and Wohlschlaeger 
are encouraging, there is more or less consent that the clini-
cal cardiac improvement and performance are less pro-
nounced in the majority of cases and only a small subset of 
patients can be weaned from the device and live without 
transplantation. The approach described by Birks and co-
workers consisting of combined use of mechanical support 
and medical treatment including clenbuterol holds promising 
results for the future, as the percentage of patients who can 
be weaned is reported to be considerably higher. Another 
important problem in this field is the absence of a suitable 
serum/plasma biomarker that accurately indicates cardiac 
recovery under LVAD therapy and could possibly predict the 
clinical outcome and the changes for successful weaning 
from the device. ANP and BNP levels are widely used, but 
these molecules are mainly stretch-induced and levels de-
crease under support because of volume and pressure reduc-
tion, but not necessarily indicate “reverse remodeling” or 
clinical recovery. We could not show Chromogranin A se-
rum levels to be usable biomarker for this group of patients. 
Gene expression profiles as performed by Birks et al. might 
serve as a possible read out frame for the future helping to 
identify patients who can be weaned from the device. How-
ever, the master molecular switches orchestrating the process 
of “reverse remodeling” are still unknown. The heterogene-
ity of patients concerning the underlying aetiology of CHF, 
the duration of support, the type of LVAD implanted and 
medication causes further difficulties, although we never 
found these parameters to be influential on the parameters 
investigated. In conclusion, despite the limited clinical im-
provement occurring only in a subset of patients, a better 
understanding of the underlying biological mechanisms of 
cardiac “reverse remodeling” is crucial for the development 
of future therapeutic strategies in this still intriguing scien-
tific field.  
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